Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 9, No. 4, 2009
Issue release date: June 2009
Section title: Original Paper
Free Access
Pancreatology 2009;9:410–419

Nuclear Magnetic Resonance Spectroscopy-Based Metabolomics of the Fatty Pancreas: Implicating Fat in Pancreatic Pathology

Zyromski N.J.a · Mathur A.a · Gowda G.A.N.b · Murphy C.b · Swartz-Basile D.A.a · Wade T.E.a · Pitt H.A.a · Raftery D.b
aDepartment of Surgery, Indiana University, Indianapolis, Ind., and bDepartment of Chemistry, Purdue University, West Lafayette, Ind., USA
email Corresponding Author

Nicholas J. Zyromski, MD

Department of Surgery, Indiana University School of Medicine

535 Barnhill Drive, RT 130

Indianapolis, IN 46202 (USA)

Tel. +1 317 274 5012, Fax +1 317 274 4554, E-Mail nzyromsk@iupui.edu

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: Obesity is a worldwide epidemic and a significant risk factor for pancreatic diseases including pancreatitis and pancreatic cancer; the mechanisms underlying this association are unknown. Metabolomics is a powerful new analytical approach for describing the metabolome (compliment of small molecules) of cells, tissue or biofluids at any given time. Our aim was to analyze pancreatic fat content in lean and congenitally obese mice using both metabolomic analysis and conventional chromatography. Methods: The pancreatic fat content of 12 lean (C57BL/6J), 12 obese leptin-deficient (Lepob) and 12 obese hyperleptinemic (Lepdb) mice was evaluated by metabolomic analysis, thin-layer and gas chromatography. Results: Pancreata of congenitally obese mice had significantly more total pancreatic fat, triglycerides and free fatty acids, but significantly less phospholipids and cholesterol than those of lean mice. Metabolomic analysis showed excellent correlation with thin-layer and gas chromatography in measuring total fat, triglycerides and phospholipids. Conclusions: Differences in pancreatic fat content and character may have important implications when considering the local pancreatic proinflammatory milieu in obesity. Metabolomic analysis is a valid, powerful tool with which to further define the mechanisms by which fat impacts pancreatic disease.

© 2009 S. Karger AG, Basel and IAP

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: September 15, 2008
Accepted: January 23, 2009
Published online: May 19, 2009
Issue release date: June 2009

Number of Print Pages: 10
Number of Figures: 3
Number of Tables: 2

ISSN: 1424-3903 (Print)
eISSN: 1424-3911 (Online)

For additional information: http://www.karger.com/PAN

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.